Phase II study of topotecan and thalidomide in patients with high-risk myelodysplastic syndromes

Leukemia and Lymphoma

Volumn 47, Issue 3, 2006, Pages 433-440

  Raza, Azra ^a   Lisak, Laurie ^a   Billmeier, Jennifer ^a   Pervaiz, Hassan ^a   Mumtaz, Muhammad ^a   Gohar, Samreen ^a   Wahid, Khalid ^a   Galili, Naomi ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Induction therapy; Myelodysplastic syndrome; Phase II trial; Thalidomide; Topotecan

Indexed keywords

ANTINEOPLASTIC AGENT; THALIDOMIDE; TOPOTECAN;

ADULT; AGED; ANEMIA; ARTICLE; BLAST CELL; BLOOD TOXICITY; BLOOD TRANSFUSION; BONE MARROW CELL; CANCER MORTALITY; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HIP SURGERY; HUMAN; HUMAN CELL; INFECTION COMPLICATION; MALE; MYELODYSPLASTIC SYNDROME; NEUROPATHY; NEUTROPENIA; PAIN; PATIENT MONITORING; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; REFRACTORY ANEMIA WITH EXCESS BLASTS; REFRACTORY ANEMIA WITH EXCESS BLASTS IN TRANSFORMATION; SIDE EFFECT; SWEATING; SYNCOPE; THROMBOCYTOPENIA; WEAKNESS;

AGED; ANEMIA, REFRACTORY, WITH EXCESS OF BLASTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; DRUG TOLERANCE; FEMALE; HUMANS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; RISK FACTORS; THALIDOMIDE; TIME FACTORS; TOPOTECAN; TREATMENT OUTCOME;

EID: 30844449252     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.1080/10428190500353943     Document Type: Article

References (30)

1. Raza, A and Mundle, S and Shetty, V and Alvi, S and Chopra, H and Span, L and (1996) A paradigm shift in myelodysplastic syndromes Leukemia, 10, pp. 1648-1652.
2. Heaney, M and Golde, D. (1999) Myelodysplasia N Engl J Med, 340, pp. 1649-1660.
3. Greenberg, P and Cox, C and LeBeau, M and Fenaux, P and Morel, P and Sanz, G and (1997) International scoring system for evaluating prognosis in myelodysplastic syndromes Blood, 89, pp. 2079-2088.
4. Kimby, E and Nygren, P and Glimelius, B. (2001) A systematic overview of chemotherapy effects in acute myeloid leukemia Acta Oncol, 40, pp. 231-252.
5. Tohyama, K and Tsutani, H and Wano, Y and Iwasaki, H and Fukushima, T and Urasaki, Y and (1997) Anti-leukemia chemotherapy of high-risk myelodysplastic syndromes Oncologist, 2, pp. 160-163.
6. Buchner, T and Hiddemann, W and Berdel, W and Wormann, B and Loffler, H and Schoch, C and (2001) Remission induction therapy: The more intensive the better? Cancer Chemother Pharmacol, 48(Suppl 1), pp. S41-S44.
7. Estey, E. (1998) Incorporating new modalities into guidelines. Topotecan for myelodysplastic syndromes Oncology (Huntingt), 12, pp. 81-86.
8. Garcia-Carbonero, R and Supko, J. (2002) Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins Clin Cancer Res, 8, pp. 641-661.
9. Cooper, B and Donaher, E and Lazarus, H and Green, S and Gosky, D and Rosenthal, N and (2003) A phase I and pharmacodynamic study of sequential topotecan and etoposide in patients with relapsed or refractory acute myelogenous and lymphoblastic leukemia Leuk Res, 27, pp. 35-44.
10. Mainwaring, M and Rimsza, L and Chen, S and Gomez, S and Weeks, F and Reddy, V and (2002) Treatment of refractory acute leukemia with timed sequential chemotherapy using topotecan followed by etoposide + mitoxantrone (T-EM) and correlation with topoisomerase II levels Leuk Lymphoma, 43, pp. 989-999.
11. Miller, C. (2000) Myelodysplastic syndromes Curr Treat Options Oncol, 1, pp. 63-69.
12. Gore, S and Rowinsky, E and Miller, C and Griffin, C and Chen, T and Borowitz, M and (1998) A phase II 'window' study of topotecan in untreated patients with high risk adult acute lymphoblastic leukemia Clin Cancer Res, 4, pp. 2677-2689.
13. Beran, M and Estey, E and O'Brien, S and Giles, F and Koller, C and Kornblau, S and (1998) Results of topotecan single-agent therapy in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia Leuk Lymphoma, 31, pp. 521-531.
14. Kantarjian, H. (1999) New developments in the treatment of acute myeloid leukemia: Focus on topotecan Semin Hematol, 36(Suppl 8), pp. 16-25.
15. Beran, M and Estey, E and O'Brien, S and Cortes, J and Koller, C and Giles, F and (1999) Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia J Clin Oncol, 17, pp. 2819-2830.
16. Beran, M and Shen, Y and Kantarjian, H and O'Brien, S and Koller, C and Giles, F and (2001) High-dose chemotherapy in high-risk myelodysplastic syndrome: Covariate-adjusted comparison of five regimens Cancer, 92, pp. 1999-2015.
17. Raje, N and Anderson, K. (2002) Thalidomide and immunomodulatory drugs as cancer therapy Curr Opin Oncol, 14, pp. 635-640.
18. Steins, M and Padro, T and Bieker, R and Ruiz, S and Kropff, M and Kienast, J and (2002) Efficacy and safety of thalidomide in patients with acute myeloid leukemia Blood, 99, pp. 834-839.
19. Steins, M and Bieker, R and Padro, T and Kessler, T and Kienast, J and Berdel, W and (2003) Thalidomide for the treatment of acute myeloid leukemia Leuk Lymphoma, 44, pp. 1489-1493.
20. Keravich, D and Daniels, C. (1999) Challenges of thalidomide distribution in a hospital setting Am J Health Syst Pharm, 56, pp. 1721-1725.
21. Thalomid® (thalidomide) Capsules [package insert]. (1993) Warren NJ: Celgene Corporation.
22. Armstrong, D. (2004) Topotecan dosing guidelines in ovarian cancer: reduction and management of hematologic toxicity Oncologist, 9, pp. 33-42.
23. Raza, A and Yousuf, N and Abbas, A and Umerani, A and Mehdi, A and Bokhar, S and (1992) High expression of transforming growth factor-beta long cell cycle times and a unique clustering of S-phase cells in patients with acute promyelocytic leukemia Blood, 79, pp. 1037-1048.
24. Raza, A and Bokhari, J and Yousuf, N and Mehdi, A and Mazewski, C and Khan, S and (1991) Cell cycle kinetic studies in human cancers. Development of three DNA specific labels in three decades Arch Pathol Lab Med, 115, pp. 873-879.
25. Bennett, J. (2000) World Health Organization classification of the acute leukemias and myelodysplastic syndrome Int J Hematol, 72, pp. 131-133.
26. Lisak, L and Tahir, S and Billmeier, J and Willman, D and Khan, U and Pervaiz, M and (2003) Topotecan and thalidomide is an effective combination for a subset of patients with high-risk myelodysplastic syndromes (MDS). In American Society of Clinical Oncology 39th Annual Meeting Program. Chicago IL
27. Larson, R. (1996) Treatment of acute myeloid leukemia with antecedent myelodysplastic syndrome Leukemia, 10(Suppl 1), pp. S23-S25.
28. Garst, J and Campagna, L and Blackwell, S and Kelley, M and Padilla, K and Bjusrtrom, T and (2003) A phase II study of sequential topotecan and carboplatin/etoposide for the treatment of extensive stage small cell lung carcinoma (SCLC) Proc Am Soc Clin Oncol, 22, pp. 661.
29. Mok, T and Wong, H and Zee, B and Yu, K and Leung, T and Lee, T and (2002) A phase I-II study of sequential administration of topotecan and oral etoposide (topoisomerase I and II inhibitors) in the treatment of patients with small cell lung carcinoma Cancer, 95, pp. 1511-1519.
30. Silverman, L and Demakos, E and Peterson, B and Kornblith, A and Holland, J and Odchimar-Reissig, R and (2002) Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: A study of the Cancer and Leukemia Group B J Clin Oncol, 20, pp. 2429-2440.